Molecular response of a patient with e19a2-positive chronic myeloid leukemia to flumatinib: a case report and literature review
Flumatinib demonstrated excellent deep molecular response and good tolerability in e19a2-positive CML patients, suggesting that it may be one of the preferred treatment options for such patients.
Authors
- Caiqin Mu
- Yaqing Feng (ORCID: https://orcid.org/0000-0001-7763-7470)
- Jun Qiao (ORCID: https://orcid.org/0000-0001-5210-4379)
- J Y Gong (ORCID: https://orcid.org/0000-0003-4172-9917)
- Hongjin Wang (ORCID: https://orcid.org/0009-0008-8649-7535)
- Lidong Zhang (ORCID: https://orcid.org/0000-0002-4924-1927)
- Xi Liu (ORCID: https://orcid.org/0000-0003-4927-8292)
- Yanfang Zhang (ORCID: https://orcid.org/0000-0001-7614-0067)
- Haitao Meng
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Shanxi Datong University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3389/fmed.2025.1515002
- Citations
- 2
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54